Commercial genomics analysis did not reveal any clinically actionable mutations, but RNA-seq analysis showed that the tumor was of the luminal androgen receptor subtype30, with AR mRNA expressed in all tumor clones and AR protein detected in a subset of cells by clinical IHC (Extended Data Fig. 10c). The gene discussed is AR; the disease is neoplasm.